A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries.

During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

New findings reveal promising efficacy of irpagratinib and atezolizumab in treating advanced hepatocellular carcinoma with ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Zev A. Wainberg, MD, discussed the significance of the immune response signals in a phase 1 trial of an amphiphile vaccine for pancreatic cancer.

Jason Luke, MD, FACP, discusses the mechanism of action of IMA203, a novel agent for the treatment of metastatic melanoma.

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and ...

A promising allogeneic CAR-T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments ...

New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...